RxDoctor Payments Data

Alexa Kaufman

Psychiatric/Mental Health · Dublin, OHNPI 1164076063

Payments from drug & device makers

$3,108in general payments, 2019–2025

Across 113 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$533
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$469
  • Johnson & Johnson$383
  • Supernus Pharmaceuticals, Inc.$170
  • Otsuka America Pharmaceutical, Inc.$150
  • plus $307 from 9 others

What the payments were for

  • Food & beverage$2,80290%
  • Education$30510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,108 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$5,809
Medicare patients
13
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl12$34,167
Quetiapine Fumarate71$1,246
Vilazodone Hcl15$1,092
Aripiprazole26$824
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$710
Buspirone Hcl44$609
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$528
Lamotrigine47$508
Hydroxyzine Pamoate27$384
Duloxetine Hcl12$356
Venlafaxine Hcl23$312
Venlafaxine Hcl ErVenlafaxine Hcl15$233
Hydroxyzine Hcl16$218
Escitalopram Oxalate15$201
Propranolol Hcl12$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$383$34,16712 claims
Almatica Pharma LLCSertraline Hcl$29$9827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →